7-Hydroxystaurosporine
- Generic Name
- 7-Hydroxystaurosporine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H26N4O4
- CAS Number
- 112953-11-4
- Unique Ingredient Identifier
- 7BU5H4V94A
- Associated Conditions
- -
- Associated Therapies
- -
UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00045747
- Locations
- ๐บ๐ธ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00039403
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-08-09
- Target Recruit Count
- 30
- Registration Number
- NCT00047242
- Locations
- ๐บ๐ธ
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- University Health Network, Toronto
- Registration Number
- NCT00045513
- Locations
- ๐จ๐ฆ
Princess Margaret Hospital at University Health Network, Toronto, Ontario, Canada
๐จ๐ฆMcMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
๐จ๐ฆLondon Health Sciences Centre, London, Ontario, Canada
UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT00030888
- Locations
- ๐บ๐ธ
UCSF Comprehensive Cancer Center, San Francisco, California, United States
๐บ๐ธVeterans Affairs Medical Center - San Francisco, San Francisco, California, United States
UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00042861
- Locations
- ๐บ๐ธ
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019838
- Locations
- ๐บ๐ธ
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
๐บ๐ธNCI - Center for Cancer Research, Bethesda, Maryland, United States
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 33
- Registration Number
- NCT00045175
- Locations
- ๐จ๐ฆ
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
๐จ๐ฆMargaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
๐จ๐ฆPrincess Margaret Hospital, Toronto, Ontario, Canada
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00045500
- Locations
- ๐บ๐ธ
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
๐บ๐ธFrederick Cancer Research and Development Center, Frederick, Maryland, United States
๐บ๐ธNCI - Center for Cancer Research, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.